NovoCure Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

NovoCureDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -41.4% zurückgegangen, während in der Branche Medical Equipment die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 14.5% pro Jahr.

Wichtige Informationen

-41.4%

Wachstumsrate der Gewinne

-37.7%

EPS-Wachstumsrate

Medical Equipment Wachstum der Industrie	12.9%
Wachstumsrate der Einnahmen	14.5%
Eigenkapitalrendite	-50.1%
Netto-Marge	-39.1%
Letzte Ertragsaktualisierung	30 Sep 2023

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie NovoCure Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

BMV:NVCR N Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Sep 23	504	-197	380	224
30 Jun 23	508	-174	354	222
31 Mar 23	522	-141	331	224
31 Dec 22	538	-93	306	206
30 Sep 22	543	-82	289	208
30 Jun 22	545	-68	279	204
31 Mar 22	538	-59	269	198
31 Dec 21	535	-58	263	201
30 Sep 21	546	-27	253	188
30 Jun 21	545	-5	246	173
31 Mar 21	527	12	232	153
31 Dec 20	494	20	225	132
30 Sep 20	450	19	216	112
30 Jun 20	409	12	206	98
31 Mar 20	380	9	197	87
31 Dec 19	351	-7	185	79
30 Sep 19	322	-27	174	70
30 Jun 19	294	-41	166	65
31 Mar 19	269	-55	158	57
31 Dec 18	248	-64	151	51
30 Sep 18	232	-59	143	46
30 Jun 18	217	-59	137	42
31 Mar 18	194	-64	131	40
31 Dec 17	177	-62	123	38
30 Sep 17	154	-73	115	37
30 Jun 17	125	-95	112	37
31 Mar 17	105	-114	108	39
31 Dec 16	83	-132	107	41
30 Sep 16	65	-143	108	44
30 Jun 16	52	-135	96	44
31 Mar 16	41	-124	85	45
31 Dec 15	33	-112	73	44
30 Sep 15	25	-102	60	44
30 Jun 15	20	-94	53	43
31 Mar 15	18	-86	49	41
31 Dec 14	15	-81	45	40
31 Dec 13	10	-77	33	35

Qualität der Erträge: NVCR N ist derzeit unrentabel.

Wachsende Gewinnspanne: NVCR N ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: NVCR N ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 41.4% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von NVCR N verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: NVCR N ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Medical Equipment (1.7%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: NVCR N hat eine negative Eigenkapitalrendite (-50.11%), da es derzeit unrentabel ist.

NovoCure Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022)

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021)

Recent updates

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Chief Financial Officer recently sold Mex$589k worth of stock

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022)

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Chief Operating Officer recently sold Mex$35m worth of stock

Chief Human Resources Officer recently sold Mex$383k worth of stock

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Insufficient new directors

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Insufficient new directors

Insufficient new directors

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021)

Insufficient new directors

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

Insufficient new directors

Executive Chairman recently sold Mex$1.2m worth of stock

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021)

Insufficient new directors

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Now 20% undervalued after recent price drop

Chief Medical Officer recently sold Mex$5.4m worth of stock

Insufficient new directors

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

General Counsel recently sold Mex$4.6m worth of stock

Insufficient new directors

Novocure Announces Resignation of Todd Longsworth as General Counsel

Insufficient new directors

President recently bought Mex$11m worth of stock

Insufficient new directors

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren